New Antibody Treatments for Triple-Negative Breast Cancer
Antibody-dual drug conjugates for eradicating triple-negative breast cancer with heterogeneity
This research aims to create advanced antibody-drug combinations to more effectively treat triple-negative breast cancer, especially its resistant forms.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Sci Ctr Houston NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11141823 on NIH RePORTER |
What this research studies
Triple-negative breast cancer can be very aggressive and difficult to treat, often becoming resistant to medicines because tumors contain different types of cancer cells. While some new antibody-based drugs like Trodelvy have been approved, cancer can still return, and patients may experience side effects. This project is developing a new type of medicine called an 'antibody-dual drug conjugate' that combines an antibody with two different cancer-fighting drugs. These new medicines are designed to target a specific protein on breast cancer cells and attack them in multiple ways, aiming to overcome resistance and reduce side effects.
Who could benefit from this research
Good fit: Patients with triple-negative breast cancer, particularly those whose cancer has shown resistance to existing treatments or has a heterogeneous cell population, would be the focus of future clinical applications.
Not a fit: Patients with other types of breast cancer or those whose triple-negative breast cancer does not express the TROP2 protein may not benefit from this specific approach.
Why it matters
Potential benefit: If successful, this new treatment could offer a more effective and less toxic option for patients with triple-negative breast cancer, especially those whose cancer has become resistant to current therapies.
How similar studies have performed: Antibody-drug conjugates have shown success in treating triple-negative breast cancer, but this approach aims to improve upon existing methods by combining two drugs for enhanced efficacy and reduced resistance.
Where this research is happening
Houston, United States
- University of Texas Hlth Sci Ctr Houston — Houston, United States (Active)
Researchers
- Principal investigator: Tsuchikama, Kyoji — University of Texas Hlth Sci Ctr Houston
- Study coordinator: Tsuchikama, Kyoji
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.